


## Amendments to the Claims

### Listing of Claims

1. (Previously Presented) A method for treating acute coronary syndrome, high risk vascular disease or cerebrovascular aneurysm and recurrence thereof, in a patient in need thereof, comprising the following steps performed in any order:

- a) administering a compound of formula I




I

or a pharmaceutically acceptable salt thereof; and

- b) performing a percutaneous coronary intervention procedure.

2. (Currently Amended) A method for treating according to Claim 1 wherein the compound of formula I is administered in combination with aspirin. ~~acute coronary syndrome, high risk vascular disease or cerebrovascular aneurysm and recurrence thereof, in a patient in need thereof, comprising the following steps performed in any order:~~

- ~~a) administering a compound of formula I~~




~~I~~

~~or a pharmaceutically acceptable salt thereof in combination with aspirin; and~~

- b) ~~performing a percutaneous coronary intervention procedure.~~

3. (Previously Presented) A method for treating acute coronary syndrome, high risk vascular disease or cerebrovascular aneurysm and recurrence thereof, in a patient in need thereof, comprising the following steps performed in the order described:

- a) first, administering a compound of formula I



I

or a pharmaceutically acceptable salt thereof, optionally in combination with aspirin;

- b) second, performing a percutaneous coronary intervention procedure;  
and  
c) third, administering a compound of formula I or a pharmaceutically acceptable salt thereof, optionally in combination with aspirin.

4. (Previously Presented) A method for treating acute coronary syndrome, high risk vascular disease or cerebrovascular aneurysm and recurrence thereof, in a patient in need thereof, comprising in order the steps of:

- a) administering a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, optionally in combination with aspirin about 2 to 30 days prior to performing the percutaneous coronary intervention procedure,  
b) performing a percutaneous coronary intervention procedure, and  
c) administering a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, optionally in combination with aspirin about 0 to 365 days after performance of the percutaneous coronary intervention procedure.

5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)